Prevalence of Helicobacter Pylori Infection in Patients with Some Inflammatory Eyelid Diseases

Purpose. To determine the prevalence of Helicobacter pylori in patients with inflammatory diseases of the eyelids (chronic blepharitis, chalazion) and to identify the relationship between the presence of this bacterium in the body and these diseases. Materials and methods. The study included 56 patients with chronic blepharitis of various etiologies, 70 patients with chalazion who sought consultation in the short-term hospital department (SKP) at the city clinical hospital named after. V.M. Buyanov of the Moscow City Health Department, from 01/10/2022 to 01/10/2023. All patients underwent a standard ophthalmological examination. Results. The patients’ visual acuity ranged from 0.5 to 0.8 without correction. A positive 13C-urease test was found in 17 (30.4%) of 56 patients with blepharitis, and in 21 (30%) of 70 patients with chalazion. Among patients with chronic blepharitis and a positive 13C-urease test, scaly blepharitis was observed in 11 (64.7%) patients, rosacea-blepharitis in 3 (17.6%), demodectic blepharitis in 2 (11.7%) and mixed blepharitis in 1 (5.8%). In the group of patients with chronic blepharitis, the prevalence of scaly blepharitis tended to decrease with age, whereas the prevalence of rosacea and demodectic blepharitis tended to increase. Conclusion. This study showed a relationship between the persistence of Helicobacter pylori and the development of chronic blepharitis and chalazion. Chronic blepharitis is a disease of high scientific interest because it may be a clinical sign of internal infection. We believe that the work done will serve as the basis for a better understanding of the pathogenetic processes of the relationship between the digestive system and the organ of vision. The association between chronic blepharitis, chalazion, and H. pylori infection remains to be further demonstrated in a larger sample with clinical trials that may be able to provide further evidence of this association and identify areas for new therapeutic targets. © 2025 Elsevier B.V., All rights reserved.